510,600 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Acquired by Toronto Dominion Bank

Toronto Dominion Bank purchased a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 510,600 shares of the company’s stock, valued at approximately $6,760,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TAK. Farther Finance Advisors LLC lifted its position in Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after acquiring an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical during the 4th quarter worth approximately $52,000. Cromwell Holdings LLC acquired a new position in Takeda Pharmaceutical during the 4th quarter worth approximately $61,000. Venturi Wealth Management LLC lifted its position in Takeda Pharmaceutical by 554.7% during the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company’s stock worth $67,000 after acquiring an additional 4,260 shares in the last quarter. Finally, Lindbrook Capital LLC lifted its position in Takeda Pharmaceutical by 65.0% during the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company’s stock worth $68,000 after acquiring an additional 2,029 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

TAK stock opened at $14.33 on Thursday. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 52-week low of $12.58 and a 52-week high of $15.43. The stock’s 50 day moving average is $14.72 and its two-hundred day moving average is $14.01. The company has a market capitalization of $45.58 billion, a PE ratio of 35.81, a P/E/G ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The business had revenue of $7.34 billion for the quarter, compared to analysts’ expectations of $8.02 billion. Analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.